tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Tianjin Pharmaceutical Da Ren Tang Group Proposes Equity Custody Agreement to Boost Market Competitiveness

Story Highlights
  • Tianjin Pharmaceutical Da Ren Tang Group plans an equity custody agreement to enhance synergies.
  • The agreement involves managing 100% equity interest, earning an annual custody fee.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Tianjin Pharmaceutical Da Ren Tang Group Proposes Equity Custody Agreement to Boost Market Competitiveness

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S ( (DE:2TZ) ) just unveiled an announcement.

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited has announced its proposal to enter into an equity custody agreement with Tianjin Medicine Asset Management Co., Ltd. and Tianjin Pharmaceutical Group Jin Yi Tang Chain Co., Ltd. This agreement aims to enhance business synergies, coordinate resources, and improve market competitiveness. The company will exercise all shareholder rights for 100% of the equity interest in the target company for a three-year period, receiving an annual custody fee. This move is expected to strengthen the company’s operations without altering its financial statement consolidation.

More about Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited, is a company incorporated in the People’s Republic of China. It operates in the pharmaceutical industry, focusing on enhancing business synergies with pharmacy retail chains and strengthening its market competitiveness and long-term sustainability.

See more data about 2TZ stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1